STOCK TITAN

Biostem Tech - BSEM STOCK NEWS

Welcome to our dedicated page for Biostem Tech news (Ticker: BSEM), a resource for investors and traders seeking the latest updates and insights on Biostem Tech stock.

Overview

BioStem Technologies, Inc. (BSEM) is a pioneering MedTech company at the forefront of regenerative medicine and advanced wound care. The company is dedicated to the research, development, manufacture, and commercialization of placental-derived biologics and allografts designed to support tissue regeneration and improve clinical outcomes. Leveraging its proprietary BioREtain® processing method, BioStem transforms perinatal tissue into innovative products that preserve natural growth factors and maintain the structural integrity essential for advanced wound care applications.

Core Business and Technological Innovation

At its core, BioStem Technologies focuses on addressing the critical healthcare need for effective regenerative therapies. The company utilizes cutting-edge research in perinatal tissue to develop allografts that are not only mechanically robust but also biologically active. The BioREtain® process is a carefully designed, patented six-step procedure that minimizes tissue manipulation while preserving the endogenous biological properties. This proprietary processing methodology sets BioStem apart by ensuring that essential growth factors and cytokines remain intact, thereby enhancing the healing potential of their products.

Clinical Programs and Product Portfolio

BioStem’s clinical programs are a testament to its commitment to scientific excellence and patient care. The company has advanced several clinical trials evaluating its placental-derived allograft products for wound management and tissue repair. The diverse product portfolio includes quality brands known for their transformative applications in chronic and non-healing wounds, including but not limited to products designed for diabetic foot ulcers, surgical wound care, and other chronic conditions. Each allograft is processed at an FDA-registered facility that is AATB-accredited, ensuring adherence to the highest standards under current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP).

Operational Excellence and Regulatory Adherence

The company excels in operational efficiency and quality management. BioStem Technologies applies stringent quality assurance procedures integral to its ability to maintain FDA registration and AATB accreditation. These robust quality management systems and standard operating procedures ensure that every product meets rigorous criteria for safety, efficacy, and consistency. This unwavering commitment to excellence not only supports regulatory compliance but also reinforces the company’s reputation for reliability in the MedTech space.

Strategic Initiatives and Market Position

Operating within a highly competitive MedTech landscape, BioStem has established itself as a nimble, research-oriented entity capable of navigating complex regulatory frameworks and market dynamics. The company’s strategic initiatives include robust clinical research, targeted product development, and actively pursuing partnerships that extend its market reach into niche segments such as advanced wound care and regenerative therapies. By continuously optimizing its product pipeline, BioStem is well positioned to meet the evolving demands of healthcare providers and patients seeking innovative alternatives to traditional wound care therapies.

Collaborations and Industry Impact

Partnerships and collaborations are central to BioStem’s approach. The company works closely with renowned healthcare institutions, regulatory bodies, and distribution partners to expand the accessibility and adoption of its advanced biologics. Such collaborations reinforce its market credibility and provide the clinical data necessary to build trust with the medical community. Peer-reviewed studies and clinical trial outcomes further attest to the superior performance of BioStem’s products, positioning them as viable, transformative options within the regenerative medicine and wound care markets.

Research-Driven Culture and Future-Proofing

BioStem Technologies maintains a strong focus on research and development to ensure continuous improvement of its product offerings. By investing in state-of-the-art clinical trials and innovative technologies, the company harnesses deep scientific insights to refine its proprietary methods and expand its product portfolio. This research-driven culture not only fosters innovation but also provides the foundation for sustained competitive differentiation in an industry where precise technological execution is essential for success.

Summary

In summary, BioStem Technologies, Inc. is a company that combines groundbreaking technological innovation with a rigorous commitment to quality and regulatory standards. Its proprietary BioREtain® process, advanced clinical programs, and strategic operational initiatives exemplify its dedication to harnessing natural biological properties for transformative wound care and regenerative therapies. With a strong operational framework and an unwavering focus on research and development, BioStem continues to enhance its position within the competitive MedTech landscape, delivering solutions that are both scientifically innovative and clinically impactful.

This comprehensive overview provides insight into the company’s robust business model, its commitment to maintaining the highest quality standards, and its strategic approach to addressing unmet needs in advanced wound care and regenerative medicine. Whether you are a healthcare provider, clinical researcher, or an informed stakeholder, understanding BioStem’s approach to innovation and quality provides a clear perspective on its role in reshaping the future of regenerative therapies.

Rhea-AI Summary

BioStem Technologies (OTC: BSEM) has requested an extension for filing its 2024 annual report with the OTC. The delay is attributed to an ongoing SEC review process of the company's Form 10 registration statement, which could affect financial statements and disclosures.

The company expects to file the annual report by April 15, 2025, the extension period's deadline. Management indicates this review process is a necessary step in their planned Nasdaq uplisting. A webcast covering Q4 and year-end 2024 results will be announced following the completion of the SEC review.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.81%
Tags
none
-
Rhea-AI Summary

BioStem Technologies (OTC: BSEM) has received Notice of Allowance from the USPTO for two patent applications, strengthening its intellectual property portfolio in advanced wound care technology. The company currently holds 43 issued patents and has 26 pending applications.

The first patent (No. 18/593,225) covers novel micronized human placental compositions for wound care, specifically designed for wound packing, irregular surfaces, weeping wounds, and dental/oral applications. The second patent (No. 18/290,914) pertains to sterile human placental allograft compositions manufactured with the BioRetain® process, aimed at treating conditions like diabetic foot ulcers and dental wounds.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.81%
Tags
none
-
Rhea-AI Summary

BioStem Technologies (OTC: BSEM) announces its participation in the 24th Annual Needham Virtual Healthcare Conference, where CEO Jason Matuszewski will present on April 10, 2025, at 1:30 PM ET. The company will also conduct investor meetings during the conference.

BioStem Technologies specializes in developing and manufacturing placental-derived products for advanced wound care using their proprietary BioREtain® processing method. Their product portfolio includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®.

The company maintains AATB accreditation and operates an FDA-registered facility in Pompano Beach, Florida, following Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP). Their processing method focuses on maintaining growth factors and preserving tissue structure for optimal wound care solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.24%
Tags
conferences
Rhea-AI Summary

BioStem Technologies (OTC: BSEM) has received Institutional Review Board (IRB) approval for a clinical study evaluating its proprietary BioREtain® Amnion Chorion (BR-AC) for treating venous leg ulcers (VLU). The multicenter, randomized, controlled study will enroll at least 60 subjects across 15 U.S. sites, comparing BR-AC to standard care over 12 weeks.

The trial will focus on patients with non-healing, non-infected VLUs with confirmed venous reflux. Subjects will undergo a two-week run-in period with standard wound care before randomization. The primary objective is to assess whether BR-AC increases complete wound closure likelihood compared to standard care alone.

This marks BioStem's third prospective clinical trial across various wound indications. The company's BioREtain® technology is designed to retain tissue's native properties while maintaining the structure and matrix found in fresh perinatal tissue. The VLU market is growing at over 4% CAGR, affecting up to two million people annually in the United States.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.31%
Tags
-
Rhea-AI Summary

BioStem Technologies (OTC: BSEM) announced preliminary financial results for Q4 and the full year ending December 31, 2024. Q4 net revenue is expected to be around $102.9 million, representing a 794% increase over Q4 2023. Full-year 2024 net revenue is projected at $301.8 million, a 1,702% increase from $16.7 million in 2023. Q4 gross profit is anticipated to be approximately $99.3 million, up 811% from $10.9 million in Q4 2023. Full-year gross profit is expected to reach $288.1 million, a 1,775% increase from $15.4 million in 2023.

This growth is driven by the adoption of AmnioWrap2 OneView™ and the launch of Vendaje AC®, supported by targeted strategies from Venture Medical, The Venture OneView™ platform has played a important role in market expansion and product adoption. CEO Jason Matuszewski highlighted the transformative year and the strategic initiatives that fueled the revenue growth. He also mentioned the potential finalization of an LOI with ProgenaCare, which would expand BioStem's product portfolio.

BioStem's proprietary BioREtain® method preserves the biological properties of placental tissue, enhancing its wound treatment capabilities. BioStem's products are developed following stringent quality standards, accredited by the American Association of Tissue Banks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
none
-
Rhea-AI Summary

BioStem Technologies (OTC: BSEM) has launched the BR-AM-DFU clinical trial to evaluate its Vendaje® product against standard care for treating non-healing diabetic foot ulcers (DFUs). The multicenter, randomized study will enroll 60 patients across twelve U.S. sites, assessing wound closure over a 12-week treatment period.

This marks the company's second active clinical trial, following the BR-AC-DFU-101 trial initiated in October 2024 for AmnioWrap2™. The trials aim to demonstrate the effectiveness of BSEM's proprietary BioREtain® technology in wound care. According to market statistics, approximately 15% of diabetic patients develop foot ulcers, with treatment costs ranging from $9-13 billion annually in the U.S. In 2023, 2.2 million patients received DFU treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.27%
Tags
Rhea-AI Summary

BioStem Technologies (OTC: BSEM) has announced that CEO Jason Matuszewski will present a corporate overview at the Biotech Showcase 2025 conference in San Francisco. The presentation is scheduled for Monday, January 13, 2025, at 2:30 PM PT on Track Yosemite-C and will be available via webcast.

The conference, now in its 17th year, brings together biotechnology investors and pharmaceutical executives from around the world. BioStem's senior management will also be available for one-on-one meetings during the event, which runs from January 13-15, 2025.

BioStem Technologies specializes in developing and manufacturing placental-derived products for advanced wound care using their proprietary BioREtain® processing method. The company's portfolio includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®, all processed at their FDA registered and AATB accredited facility in Pompano Beach, Florida.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
conferences
-
Rhea-AI Summary

BioStem Technologies (OTC: BSEM) has received a Notice of Allowance from the USPTO for its patent application covering sterile human placental allografts with slits, openings, and fenestrations. The patent (No. 12,144,831) will grant on November 19, 2024, marking the first patent granted for tabular fenestrated allografts. The technology features flaps that allow exudate escape while maintaining surface area, suitable for acute and chronic wound care. The company's IP portfolio now includes 42 issued patents and 27 pending applications. The product, utilizing BioStem's BioREtain® process, is under development and will follow the HCT/P regulatory pathway.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.39%
Tags
none
-
Rhea-AI Summary

BioStem Technologies (OTC: BSEM) has signed a Letter of Intent to acquire commercial-stage products and development technologies from ProgenaCare Global. The acquisition includes ProgenaMatrix, the first commercially available human keratin matrix for wound care, and revyve Antimicrobial Wound Gel. The deal aims to expand BioStem's wound care portfolio and leverage its commercial infrastructure. ProgenaMatrix is FDA 510(k) cleared for various indications including venous stasis ulcers and diabetic foot ulcers. The transaction is expected to be finalized within 60 days, subject to regulatory approvals and Board consent.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.23%
Tags
Rhea-AI Summary

BioStem Technologies (BSEM) reported record Q3 2024 revenue of $82.6 million, up from $3.5 million in Q3 2023, marking their third consecutive quarter of record growth. The company achieved $199.0 million in revenue for the first nine months of 2024, with a gross profit margin of 94.9%. Q3 net income reached $6.8 million ($0.42 per share), compared to a loss of $1.5 million in Q3 2023. The growth was primarily driven by strong sales of AmnioWrap2® allografts. The company has filed for Nasdaq uplisting and initiated nationwide launch of Vendaje AC® following Medicare reimbursement approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags

FAQ

What is the current stock price of Biostem Tech (BSEM)?

The current stock price of Biostem Tech (BSEM) is $8.45 as of April 3, 2025.

What is the market cap of Biostem Tech (BSEM)?

The market cap of Biostem Tech (BSEM) is approximately 166.5M.

What is BioStem Technologies’ primary focus?

BioStem Technologies is dedicated to the development, manufacture, and commercialization of placental-derived allografts for regenerative therapies and advanced wound care.

How does BioStem differentiate its products?

The company utilizes its proprietary BioREtain® processing method which preserves natural growth factors and tissue structure, ensuring clinical efficacy and superior healing outcomes.

What quality certifications does BioStem adhere to?

BioStem’s products are manufactured in an FDA-registered and AATB-accredited facility, following current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP).

Which clinical applications are targeted by BioStem’s products?

Their allografts are primarily used in treating chronic wounds, including diabetic foot ulcers and surgical wound care, making them essential in regenerative medicine and advanced wound care.

How does the proprietary BioREtain® technology benefit patients?

BioREtain® ensures that the critical biological components of perinatal tissue are maintained during processing, which enhances tissue regeneration and improves healing efficiency in patients.

Who are the intended users of BioStem’s products?

The products are designed for healthcare providers and patients in need of innovative regenerative solutions, particularly those facing challenges with non-healing wounds and tissue repair.

How does BioStem maintain operational excellence?

The company invests in rigorous quality control, adherence to regulatory standards, and ongoing clinical research, which collectively ensure that its products meet the highest safety and efficacy standards.

What role do clinical trials play in BioStem’s strategy?

Clinical trials are central to BioStem’s approach, providing robust data on the effectiveness of its products and supporting regulatory approvals and market acceptance in the competitive MedTech sector.
Biostem Tech

OTC:BSEM

BSEM Rankings

BSEM Stock Data

166.47M
9.35M
Biotechnology
Healthcare
Link
United States
Pompano Beach